Pyxis Oncology, Inc. Operating Lease, Expense
Pyxis Oncology, Inc. (PYXS) reported Operating Lease, Expense of $467.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-13
- Pyxis Oncology, Inc. operating lease, expense for the quarter ending 2026-06-30 was $239.00K, a 18.32% increase year-over-year.
- Pyxis Oncology, Inc. operating lease, expense for the quarter ending 2026-03-31 was $228.00K, a 18.13% increase year-over-year.
- Pyxis Oncology, Inc. operating lease, expense for the quarter ending 2025-12-31 was $219.00K, a 17.74% increase year-over-year.
- Pyxis Oncology, Inc. operating lease, expense for the quarter ending 2025-09-30 was $210.00K, a 17.32% increase year-over-year.
- Pyxis Oncology, Inc. operating lease, expense for fiscal 2025 was $824.00K, a 17.71% increase from fiscal 2024.
- Pyxis Oncology, Inc. operating lease, expense for fiscal 2024 was $700.00K, a 6.06% increase from fiscal 2023.
- Pyxis Oncology, Inc. operating lease, expense for fiscal 2023 was $660.00K, a 41.44% decline from fiscal 2022.
- Pyxis Oncology, Inc. operating lease, expense for fiscal 2022 was $1.13M, a 86.59% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $239.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $467.00K 10-Q · filed 2026-08-13 | $686.00K derived: sum of 3 quarters · filed 2026-08-13 | $896.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $228.00K 10-Q · filed 2026-05-14 | $447.00K derived: sum of 2 quarters · filed 2026-05-14 | $657.00K derived: sum of 3 quarters · filed 2026-05-14 | $859.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $429.00K derived: sum of 2 quarters · filed 2026-03-23 | $631.00K derived: sum of 3 quarters · filed 2026-08-13 | $824.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $412.00K derived: sum of 2 quarters · filed 2026-08-13 | $605.00K 10-Q · filed 2025-11-03 | $791.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $395.00K 10-Q · filed 2026-08-13 | $581.00K derived: sum of 3 quarters · filed 2026-08-13 | $760.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $193.00K 10-Q · filed 2026-05-14 | $379.00K derived: sum of 2 quarters · filed 2026-05-14 | $558.00K derived: sum of 3 quarters · filed 2026-05-14 | $729.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $365.00K derived: sum of 2 quarters · filed 2026-03-23 | $536.00K derived: sum of 3 quarters · filed 2026-03-23 | $700.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $179.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $350.00K derived: sum of 2 quarters · filed 2025-11-03 | $514.00K 10-Q · filed 2025-11-03 | $701.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $335.00K 10-Q · filed 2025-08-14 | $522.00K derived: sum of 3 quarters · filed 2025-08-14 | $676.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $164.00K 10-Q · filed 2025-05-15 | $351.00K derived: sum of 2 quarters · filed 2025-05-15 | $505.00K derived: sum of 3 quarters · filed 2025-05-15 | $680.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $187.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $341.00K derived: sum of 2 quarters · filed 2025-03-18 | $516.00K derived: sum of 3 quarters · filed 2025-03-18 | $660.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $154.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $329.00K derived: sum of 2 quarters · filed 2024-11-12 | $473.00K 10-Q · filed 2024-11-12 | $745.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $175.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $319.00K 10-Q · filed 2024-08-14 | $591.00K derived: sum of 3 quarters · filed 2024-08-14 | $898.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $144.00K 10-Q · filed 2024-05-14 | $416.00K derived: sum of 2 quarters · filed 2024-05-14 | $723.00K derived: sum of 3 quarters · filed 2024-05-14 | $1.04M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $272.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $579.00K derived: sum of 2 quarters · filed 2024-03-21 | $895.00K derived: sum of 3 quarters · filed 2024-03-21 | $1.13M 10-K · filed 2024-03-21 |
| 2022-09-30 | $307.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $623.00K derived: sum of 2 quarters · filed 2023-11-07 | $855.00K 10-Q · filed 2023-11-07 | $1.01M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $316.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $548.00K 10-Q · filed 2023-08-11 | $704.00K derived: sum of 3 quarters · filed 2023-08-11 | $857.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $232.00K 10-Q · filed 2023-05-11 | $388.00K derived: sum of 2 quarters · filed 2023-05-11 | $541.00K derived: sum of 3 quarters · filed 2023-05-11 | $619.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $309.00K derived: sum of 2 quarters · filed 2023-03-22 | $387.00K derived: sum of 3 quarters · filed 2023-03-22 | $604.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $153.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $231.00K derived: sum of 2 quarters · filed 2022-11-01 | $448.00K 10-Q · filed 2022-11-01 | $524.00K derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $295.00K 10-Q · filed 2022-08-15 | $371.00K derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | $217.00K 10-Q · filed 2022-05-13 | $293.00K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $365.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $289.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |